The specter of generic challenges has repeatedly loomed over copyright’s famous drug, Viagra, raising questions about the future of related drug stakes. While early years saw substantial profits, the patent lapse has allowed the door for discounted copies, likely reducing profitability and creating a genuine hazard for stakeholders seeking stable